Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug. 2003

Kimiyasu Kato, and Norio Yasui-Furukori, and Takashi Fukasawa, and Toshiaki Aoshima, and Akihito Suzuki, and Muneaki Kanno, and Koichi Otani
Department of Neuropsychiatry, Yamagata University School of Medicine, Yamagata, Japan.

The effects of itraconazole, a potent inhibitor of cytochrome P450 (CYP) 3A4, on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug were studied. Ten healthy male volunteers received itraconazole 100 mg/d or placebo for 14 days in a double-blind randomized crossover manner, and on the fourth day of the treatment they received a single oral 20-mg dose of quazepam. Blood samplings and evaluation of psychomotor function by the Digit Symbol Substitution Test and Stanford Sleepiness Scale were conducted up to 240 h after quazepam dosing. Itraconazole treatment did not change the plasma kinetics of quazepam but significantly decreased the peak plasma concentration and area under the plasma concentration-time curve of 2-oxoquazepam and N-desalkyl-2-oxoquazepam. Itraconazole treatment did not affect either of the psychomotor function parameters. The present study thus suggests that CYP 3A4 is partly involved in the metabolism of quazepam.

UI MeSH Term Description Entries
D006993 Hypnotics and Sedatives Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. Hypnotic,Sedative,Sedative and Hypnotic,Sedatives,Hypnotic Effect,Hypnotic Effects,Hypnotics,Sedative Effect,Sedative Effects,Sedatives and Hypnotics,Effect, Hypnotic,Effect, Sedative,Effects, Hypnotic,Effects, Sedative,Hypnotic and Sedative
D008297 Male Males
D011597 Psychomotor Performance The coordination of a sensory or ideational (cognitive) process and a motor activity. Perceptual Motor Performance,Sensory Motor Performance,Visual Motor Coordination,Coordination, Visual Motor,Coordinations, Visual Motor,Motor Coordination, Visual,Motor Coordinations, Visual,Motor Performance, Perceptual,Motor Performance, Sensory,Motor Performances, Perceptual,Motor Performances, Sensory,Perceptual Motor Performances,Performance, Perceptual Motor,Performance, Psychomotor,Performance, Sensory Motor,Performances, Perceptual Motor,Performances, Psychomotor,Performances, Sensory Motor,Psychomotor Performances,Sensory Motor Performances,Visual Motor Coordinations
D003577 Cytochrome P-450 Enzyme System A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism. Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005479 Flurazepam A benzodiazepine derivative used mainly as a hypnotic. Apo-Flurazepam,Dalmadorm,Dalmane,Dormodor,Flurazepam Dihydrochloride,Flurazepam Hydrochloride,Flurazepam Mono-Perchlorate,Flurazepam Monohydrochloride,Staurodorm,Apo Flurazepam,Dihydrochloride, Flurazepam,Flurazepam Mono Perchlorate,Hydrochloride, Flurazepam,Mono-Perchlorate, Flurazepam,Monohydrochloride, Flurazepam
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

Kimiyasu Kato, and Norio Yasui-Furukori, and Takashi Fukasawa, and Toshiaki Aoshima, and Akihito Suzuki, and Muneaki Kanno, and Koichi Otani
June 2006, Therapeutic drug monitoring,
Kimiyasu Kato, and Norio Yasui-Furukori, and Takashi Fukasawa, and Toshiaki Aoshima, and Akihito Suzuki, and Muneaki Kanno, and Koichi Otani
January 1982, Chemotherapy,
Kimiyasu Kato, and Norio Yasui-Furukori, and Takashi Fukasawa, and Toshiaki Aoshima, and Akihito Suzuki, and Muneaki Kanno, and Koichi Otani
January 1991, European journal of clinical pharmacology,
Kimiyasu Kato, and Norio Yasui-Furukori, and Takashi Fukasawa, and Toshiaki Aoshima, and Akihito Suzuki, and Muneaki Kanno, and Koichi Otani
October 1989, Journal of pharmaceutical sciences,
Kimiyasu Kato, and Norio Yasui-Furukori, and Takashi Fukasawa, and Toshiaki Aoshima, and Akihito Suzuki, and Muneaki Kanno, and Koichi Otani
January 1983, European journal of clinical pharmacology,
Kimiyasu Kato, and Norio Yasui-Furukori, and Takashi Fukasawa, and Toshiaki Aoshima, and Akihito Suzuki, and Muneaki Kanno, and Koichi Otani
May 1993, Arzneimittel-Forschung,
Kimiyasu Kato, and Norio Yasui-Furukori, and Takashi Fukasawa, and Toshiaki Aoshima, and Akihito Suzuki, and Muneaki Kanno, and Koichi Otani
October 1975, Psychopharmacology bulletin,
Kimiyasu Kato, and Norio Yasui-Furukori, and Takashi Fukasawa, and Toshiaki Aoshima, and Akihito Suzuki, and Muneaki Kanno, and Koichi Otani
September 1998, European journal of clinical pharmacology,
Kimiyasu Kato, and Norio Yasui-Furukori, and Takashi Fukasawa, and Toshiaki Aoshima, and Akihito Suzuki, and Muneaki Kanno, and Koichi Otani
April 1984, Journal of pharmaceutical sciences,
Kimiyasu Kato, and Norio Yasui-Furukori, and Takashi Fukasawa, and Toshiaki Aoshima, and Akihito Suzuki, and Muneaki Kanno, and Koichi Otani
June 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Copied contents to your clipboard!